AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03556371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
Study NCT03556371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
Study NCT02494726 — intervention group
Intervention type: OTHER
Intervention: Thromboelastography
Description: TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
Study NCT03348709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoosmolar
Description: 48 hours, 800 ml per 24 hours
Study NCT03348709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperosmolar
Description: 48 hours, 800 ml per 24 hours
Study NCT01911585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
Study NCT01911585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
Study NCT01851070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Mesenchymal Precursor Cells
Study NCT01851070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study NCT02848703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study NCT02848703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phosphorus-31 Magnetic Resonance Spectroscopy
Study NCT02848703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium-23 MRI
Study NCT01297010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone and ondasetron
Description: Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
Study NCT01297010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
Study NCT03341065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton type robot
Study NCT03341065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: end-effector type robot
Study NCT02976753 — intervention group
Intervention type: DRUG
Intervention: efmoroctocog alfa
Description: extended half-life factor VIII product
Study NCT02976753 — intervention group
Intervention type: DRUG
Intervention: Factor VIII
Description: conventional factor VIII product
Study NCT03362190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Lucentis
Study NCT03362190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Zimura in combination with Lucentis
Study NCT03559049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 21 days
Study NCT03559049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2 IV every 21 days
Study NCT03559049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV every 21 days
Study NCT03559049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600mg PO, BID days 1-21 of each 21 day cycle
Study NCT04635995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVGN7409
Description: IV infusion once every 3 weeks (Q3W).
Study NCT00476268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone/formoterol (100/6µg) pMDI
Description: Two puffs b.i.d
Study NCT00476268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone dipropionate 250 µg/unit dose pMDI
Description: 2 inhalations bid
Study NCT00476268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol powder 12 µg/unit dose
Description: 2 inhalations bid
Study NCT04462315 — intervention group
Intervention type: DRUG
Intervention: Everolimus Eluting Coronary Stent System
Description: Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
Study NCT04462315 — intervention group
Intervention type: DEVICE
Intervention: Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)
Description: Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
Study NCT01055223 — intervention group
Intervention type: DRUG
Intervention: TZD only (RSG or PIO or troglitazone)
Description: Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
Study NCT01055223 — intervention group
Intervention type: DRUG
Intervention: TZD + spironolactone
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days.
Study NCT01055223 — intervention group
Intervention type: DRUG
Intervention: TZD + amiloride
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days.
Study NCT00950157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of information on approval based on a surrogate outcome and levels of caution
Description: Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement.
Study NCT05898451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)
Description: has a direct antitumor effect in vitro and in vivo on various tumor cell lines
Study NCT05898451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy
Description: Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
Study NCT00796510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan = 100 mg tablet administered orally, once daily
Study NCT00796510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan and Sildenafil
Description: Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
Study NCT02359604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PPI therapy
Description: PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA
Study NCT02359604 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool sample
Description: Stool sample will be obtained before initiation of PPI (before PPI therapy)
Study NCT02359604 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool sample
Description: Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
Study NCT02359604 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool sample
Description: Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
Study NCT00622908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-403
Description: 0.6% TID, 5 days
Study NCT00622908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of ISV-403 TID, 5 days
Study NCT04084756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Crisis Response Plan
Description: The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
Study NCT04084756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health Education
Description: The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
Study NCT00544765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
Study NCT00544765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX
Description: Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
Study NCT03559387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANF-RHO™
Description: Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml
Study NCT03559387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta®
Description: Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe.
Study NCT02452645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Food and Physical Activity Environments
Description: Tailored written materials, videos, telephone counseling, active toys
Study NCT02452645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Written materials, videos, books, and telephone counseling.
Study NCT02161237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: oral
Study NCT02726711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan will be infused (0.5 - 4.0 mg IV)
Study NCT02726711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 - 4.0 mg IV to be infused
Study NCT03798470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Addiction Counseling
Description: After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
Study NCT05170841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg
Description: Administered as one single tablet to be taken every 8 hours
Study NCT05170841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg
Description: Administered as one single tablet to be taken every 8 hours
Study NCT05170841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol Hydrochloride 100 mg
Description: Administered as two capsules with 50 mg each to be taken every 8 hours
Study NCT05170841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride 100 mg
Description: Administered as two capsules with 50 mg each to be taken every 8 hours
Study NCT05170841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
Study NCT03903094 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Overview of anticholinergic burden, rather than to evaluate specific drugs
Study NCT03947580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the Dvectis Single pad
Description: Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad.
Study NCT03947580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the Dvectis Double pad
Description: Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~* Categorisation of adverse events,~* Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~* Number of patients with adverse events,~* Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double
Study NCT03740347 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Response to questionnaires evaluating chronic pain and its repercussion :~* anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~* depression questionnaire (Children's Depression Inventory score),~* sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~* quality of life questionnaire (Pediatric Quality of Life inventory score).
Study NCT02740868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon-129 and Perfluoropropane (19F)
Description: Xenon gas and perfluoropropane to be inhaled by research participants
Study NCT02740868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Lung imaging will be performed for participants using MRI for all 3 arms
Study NCT02740868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Clearance Index
Description: Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
Study NCT03947580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of no pad
Description: Description is not needed
Study NCT00538343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berubicin hydrochloride (RTA 744)
Study NCT02928848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
Study NCT02928848 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
Study NCT00886483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neurofeedback
Description: A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
Study NCT00886483 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
Study NCT03076177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping application
Description: Kinesio taping application will be applied for experimental group; non specific taping application for control
Study NCT03076177 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Taping application
Description: Kinesio taping application will be applied for experimental group; non specific taping application for control
Study NCT00182091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone
Description: Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
Study NCT00182091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To maintain study-subject blinding, doses were sham adjusted.
Study NCT03246295 — intervention group
Intervention type: OTHER
Intervention: lifestyle intervention or insulin treatment
Description: Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
Study NCT02914795 — intervention group
Intervention type: OTHER
Intervention: diagnostic analysis of platelet function
Description: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
Study NCT03648437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 10Mg/mL
Description: Experimental drug
Study NCT03648437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.45% Sodium Chloride
Description: Placebo comparator
Study NCT03648437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Standard therapy
Study NCT03648437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Standard therapy
Study NCT03648437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Standard therapy
Study NCT03648437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Standard therapy
Study NCT04448522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: reduced dosage IMRT
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：63.6Gy/30Fr/2.12Gy; PTVnd：63.6Gy/30Fr/2.12Gy; PTV1：54Gy/30Fr/1.8Gy; PTV2：49.2Gy/30Fr/1.64Gy